The lung in sickle cell disease

Pediatric Pulmonology

Volumn 28, Issue 3, 1999, Pages 205-216

  Knight, Jennifer ^a,b   Murphy, Thomas M ^a   Browning, Iley ^a,c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF THE WEST INDIES   (Jamaica)

^c DRISCOLL CHILDREN S HOSPITAL   (United States)

Author keywords

Acute chest syndrome; Antioxidants; Chronic lung disease; Fat embolism; Glutathione; Nitric oxide; Sickle cell lung disease

Indexed keywords

ARTICLE; CHRONIC LUNG DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; FAT EMBOLISM; GENETIC SUSCEPTIBILITY; HUMAN; INCIDENCE; NEGRO; PNEUMONIA; PRIORITY JOURNAL; SICKLE CELL ANEMIA;

ANEMIA, SICKLE CELL; EMBOLISM, FAT; ERYTHROCYTES, ABNORMAL; HEMOGLOBIN, SICKLE; HUMANS; LUNG DISEASES;

EID: 0032824717     PISSN: 87556863     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-0496(199909)28:3<205::AID-PPUL8>3.0.CO;2-Z     Document Type: Article

References (87)

1. Jandl JH. Abnormal hemoglobin and hemoglobinopathies. In: Jandl JH, editor. Blood: pathophysiology. Boston: Blackwell Scientific Publications; 1991. p 182-195.
2. Farber MD, Koshy M, Kinney TR. Cooperative study of sickle cell disease: demographic and socioeconomic characteristics of patients and families with sickle cell disease. J Chronic Dis 1985; 38:495-505.
3. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994;330:1639-1644.
4. Serjeant GR. Distribution of sickle cell disease. In: Serjeant GR, editor. Sickle cell disease. Oxford: Oxford Medical Publications; 1985. p 13-24.
5. Vichinsky E, Williams R, Das M, Earles AN, Lewis N, Adler A, McQuitty J. Pulmonary fat embolism: a distinct cause of severe acute chest syndrome in sickle cell anemia. Blood 1994;83:3107-3112.
6. Lane PA. Sickle cell disease. Pediatr Clin North Am 1996;43: 639-664.
7. Noguchi CT, Schechter AN, Rodgers GP. Sickle cell disease pathophysiology. Baillieres Clin Haematol 1993;6:57-91.
8. Hebbel RP. Membrane-associated iron. In: Embury SH, Hebbel RP, Mohandas N, Steinberg MH, editors. Sickle cell disease: basic principles and clinical practice. New York: Raven Press, Ltd.; 1994. p 163-172.
9. Hebbel RP. Auto-oxidation and a membrane-associated "Fenton reagent": a possible explanation for development of membrane lesions in sickle erythrocytes. Clin Haematol 1985;14:129-140.
10. Hebbel RP, Eaton JW, Balasingam M, Steinberg MH. Spontaneous oxygen radical generation by sickle erythrocytes J Clin Invest 1982;70:1253-1259.
11. al-Ali AK. Erythrocyte reduced glutathione level in sickle cell anaemia and glucose-6-phosphate dehydrogenase deficient Saudi subjects. Ann Clin Biochem 1994;31:296-297.
12. Ajayi OA, George BO, Ipadeola T. Clinical trial of riboflavin in sickle cell disease. East Afr Med J 1993;70:418-421.
13. Lachant NA, Davidson WD, Tanaka KR. Impaired pentose phosphate shunt function in sickle cell disease: a potential mechanism for increased Heinz body formation and membrane lipid peroxidation. Am J Hematol 1983;15:1-13.
14. Wetterstroem N, Brewer GJ, Warth JA, Mitchinson A, Near K. Relationship of glutathione levels and Heinz body formation to irreversibly sickled cells in sickle cell anemia. J Lab Clin Med 1984;103:589-596.
15. Hebbel RP. Erythrocyte antioxidants and membrane vulnerability. J Lab Clin Med 1986;107:401-404.
16. Rank BH, Carlsson J, Hebbel RP. Abnormal redox status of membrane-protein thiols in sickle erythrocytes. J Clin Invest 1985;75: 1531-1537.
17. Tsan MF, Lawrence D, White JE. Erythrocyte insufflation-induced protection against oxygen toxicity: role of cytokines. J Appl Physiol 1991;71:1751-1757.
18. Hoidal JR, Van Asbeck BS, Mann J, Jacob HS, Kennedy TP. Therapy with red blood cells decreases hyperoxic pulmonary injury. Exp Lung Res [Suppl] 1988;14:977-985.
19. Lynch RE, Fridovich I. Permeation of the eryhthrocyte stroma by Superoxide radical. J Biol Chem 1978;253:4697-4699.
20. Toth KM, Clifford DP, Berger EM, White CW, Repine JE. Intact human erythrocytes prevent hydrogen peroxide-mediated damage to isolated perfused rat lungs and cultured bovine pulmonary artery endothelial cells. J Clin Invest 1984;74:292-295.
21. Moore CM, Ehlayel M, Leiva LE, Sorensen RU. New concepts in the immunology of sickle cell disease. Ann Allergy Asthma Immunol. 1996;76:385-400.
22. Joneckis CC, Ackley RL, Orringer EP, Wayner EA, Parise LV. Integrin alpha 4 beta 1 and glycoprotein IV (CD36) are expressed on circulating reticulocytes in sickle cell anemia. Blood 1993;82: 3548-3555.
23. Swerlick RA, Eckman JR, Kumar A, Jeitler M, Wick TM. Alpha 4 beta 1-integrin expression on sickle reticulocytes: vascular cell adhesion molecule-1-dependent binding to endothelium. Blood 1993;82:1891-1899.
24. Francis RB Jr, Haywood LJ. Elevated immunoreactive tumor necrosis factor and interleukin-1 in sickle cell disease. J Natl Med Assoc 1992;84:611-615.
25. Malave I, Perdomo Y, Escalona E, Rodriguez E, Anchustegui M, Malave H, Arends T. Levels of tumor necrosis factor alpha/ cachectin (TNF alpha) in sera from patients with sickle cell disease. Acta Haematol (Basel) 1993;90:172-176.
26. Vordermeier S, Singh S, Biggerstaff J, Harrison P, Grech H, Pearson TC, Dumonde DC, Brown KA. Red blood cells from patients with sickle cell disease exhibit an increased adherence to cultured endothelium pretreated with tumour necrosis factor (TNF). Br J Haematol 1992;81:591-597.
27. Kasschau MR, Barabino GA, Bridges KR, Golan DE. Adhesion of sickle neutrophils and erythrocytes to fibronectin. Blood 1996;87: 771-780.
28. Wick TM, Moake JL, Udden MM, McIntire LV. Unusually large von Willebrand factor multimers preferentially promote young sickle and nonsickle erythrocyte adhesion to endothelial cells. Am J Hematol 1993;42:284-292.
29. Brittain HA, Eckman JR, Swerlick RA, Howard RJ, Wick TM. Thrombospondin from activated platelets promotes sickle erythrocyte adherence to human microvascular endothelium under physiologic flow: a potential role for platelet activation in sickle cell vaso-occlusion. Blood 1993;81:2137-2143.
30. Fabry ME, Fine E, Rajanayagam V, Factor SM, Gore J, Sylla M, Nagel RL. Demonstration of endothelial adhesion of sickle cells in vivo: a distinct role for deformable sickle cell discocytes. Blood 1992;79:1602-1611.
31. Sugihara K, Sugihara T, Mohandas N, Hebbel RP. Thrombospondin mediates adherence of CD36+ sickle reticulocytes to endothelial cells. Blood 1992;80:2634-2642.
32. Klug PP, Kaye N, Jensen WN. Endothelial cell and vascular damage in the sickle cell disorders. Blood Cells 1982;8:175-184.
33. Weinstein R, Zhou MA, Bartlett-Pandite A, Wenc K. Sickle erythrocytes inhibit human endothelial cell DNA synthesis. Blood 1990;76:2146-2152.
34. Wolters HJ, ten Cate H, Thomas LL, Brandjes DP, van der Ende A, van der Heiden Y, Statius van Eps LW. Low-intensity oral anti-coagulation in sickle cell disease reverses the prethrombotic state - promises for treatment? Br J Haematol 1995;90:715-717.
35. Berney SI, Rider CD, Stephens AD, Thomas AE, Kovacs IB. Enhanced platelet reactivity and hypercoagulability in the steady state of sickle cell anaemia. Am J Hematol 1992;40:290-294.
36. el-Hazmi MA, Warsy AS, Bahakim H. Blood proteins C and S in sickle cell disease. Acta Haematol (Basel) 1993;90:114-119.
37. Marfaing-Koka A, Boyer-Neumann C, Wolf M, Leroy-Matheron C, Cynober T, Tchernia G. Decreased protein S activity in sickle cell disease. Nouv Rev Fr Hematol 1993;35:425-430.
38. Hagger D, Wolff S, Owen J, Samson D. Changes in coagulation and fibrinolysis in patients with sickle cell disease compared with healthy black controls. Blood Coagul Fibrinolysis 1995;6:93-99.
39. Kurantsin-Mills J, Ofosu FA, Safa TK, Siegel RS, Lessin LS. Plasma factor VII and thrombin-antithrombin III levels indicate increased tissue factor activity in sickle cell patients. Br J Haematol 1992;81:539-544.
40. Peters M, Plaat BE, ten Cate H, Wolters HJ, Weening RS, Brandjes DP. Enhanced thrombin generation in children with sickle cell disease. Thromb Haemost 1994;71:169-172.
41. Francis RB. Large-vessel occlusion in sickle cell disease: pathogenesis, clinical consequences, and therapeutic implications. Med Hypotheses 1991;35:88-95.
42. Francis RB Jr, Johnson CS. Vascular occlusion in sickle cell disease: current concepts and unanswered questions. Blood 1991;77: 1405-1414.
43. Serjeant G, Serjeant B, Stephens A, Roper D, Higgs D, Beckford M, Cook J, Thomas P. Determinants of haemoglobin level in steady-state homozygous sickle cell disease. Br J Haematol 1996; 92:143-149.
44. Castro O, Brambilla DJ, Thorington B, Reindorf CA, Scott RB, Gillette P, Vera JC, Levy PS. The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood 1994;84:643-649.
45. Fan LL. Evaluation and therapy of chronic interstitial pneumonias in children. Curr Opin Pediatr 1994;6:248-254.
46. Rackoff WR, Kunkel N, Silber JH, Asakura T, Ohene-Frempong K. Pulse oximetry and factors associated with hemoglobin oxygen desaturation in children with sickle cell disease. Blood 1993;81: 3422-3427.
47. Pianosi P, Charge TD, Esseltine DW, Coates AL. Pulse oximetry in sickle cell disease. Arch Dis Child 1993;68:735-738.
48. Lonsdorfer J, Bogui P, Otayeck A, Bursaux E, Poyart C, Cabannes R. Cardiorespiratory adjustments in chronic sickle cell anemia. Bull Eur Physiopathol Respir 1983;19:339-344.
49. Bromberg PA, Jensen WN. Arterial oxygen unsaturation in sickle cell disease. Am Rev Respir Dis 1967;96:400-407.
50. Craft JA, Alessandrini E, Kenney LB, Klein B, Bray G, Luban NL, Meek R, Nadkarni VM. Comparison of oxygenation measurements in pediatric patients during sickle cell crisis. J Pediatr 1994;124:93-95.
51. American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 1994;152:1107-1136.
52. Haynes J Jr, Kirkpatrick MB. The acute chest syndrome of sickle cell disease. Am J Med Sci 1993;305:326-330.
53. Vichinsky E, Styles L. Sickle cell disease: pulmonary complications. Hematol Oncol Clin North Am 1997;10:1275-1287.
54. Castro O, Brambilla DJ, Thorington B, Reindorf CA, Scott RB, Gillette P, Vera JC, Levy PS. The acute chest syndrome in sickle cell disease - incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood 1994;84:643-649.
55. Gill FM, Sleeper LA, Weiner SJ, Brown AK, Bellevue R, Grover R, Pegelow CH, Vichinsky E. Clinical events in the first decade in a cohort of infants with sickle cell disease. Blood 1995;86:776-783.
56. Gray A, Anionwu EN, Davies SC, Brozovic M. Patterns of mortality in sickle cell disease in the United Kingdom. J Clin Pathol 1991;44:459-463.
57. Horton DP, Ferriero DM, Mentzer WC. Nontraumatic fat embolism syndrome in sickle cell anemia. Pediatr Neurol 1995;12:77-80.
58. Ayers DC, Murray DG. Complications of the treatment of fractures and dislocations. In: Epps CH Jr, editor. Complications in orthopedic surgery. VoI 1. 3rd ed. Philadelphia: J.B. Lippincott Co.; 1994. p 3-47.
59. Miller GA. Fat embolism: a comprehensive review. J Oral Surg 1975;33:91-103.
60. Herndon JH, Riseborough EJ, Fischer JE. Fat embolism: a review of current concepts. J Trauma 1971;11:673-680.
61. Styles LA, Schalkwijk CG, Aarsman AJ, Vichinsky EP, Lubin BH, Kuypers FA. Phospholipase A(2) levels in acute chest syndrome of sickle cell disease. Blood 1996;87:2573-2578.
62. Baker PL, Pazell JA, Peltier LF. Free fatty acids, catecholamines, and arterial hypoxia in patients with fat embolism. J Trauma 1971; 11:1026-1030.
63. Fonte DA, Hausberger FX. Pulmonary free fatty acids in experimental fat embolism. J Trauma 1971;11:668-672.
64. Barrett-Connor E. Bacterial infection and sickle cell anemia. Medicine (Baltimore) 1971;211:97-112.
65. Kharitonov SA, Yates D, Barnes PJ. Increased nitric oxide in exhaled air of normal human subjects with upper respiratory tract infections. Eur Respir J 1996;8:295-297.
66. Gross SS, Wolin MS. Nitric oxide: pathophysiological mechanisms. Annu Rev Physiol 1995;57:737-769.
67. Wink DA, Hanbauer I, Grisham MB, Laval F, Nims RW, Laval J, Cook J, Pacelli R, Liebmann J, Krishna M, Ford PC, Mitchell JB. Chemical biology of nitric oxide: regulation and protective and toxic mechanisms. Curr Top Cell Regul 1996;34:159-187.
68. Knight JM, Kantrow S, Grayck E, Piantadosi CA, Huang YC. L-arginine produces injury in perfused lung with decreased glutathione levels. Am J Respir Crit Care Med 1995;153:739 [abstract].
69. Walker BK, Ballas SK, Burka ER. The diagnosis of pulmonary thromboembolism in sickle cell disease. Am J Hematol 1979;7: 219-232.
70. Bhalla M, Abboud MR, McLoud TC, Shepard JA, Munden MM, Jackson SM, Beaty JR, Laver JH. Acute chest syndrome in sickle cell disease: CT evidence of microvascular occlusion. Radiology 1993:187:45-49.
71. Haupt HM, Moore GW, Bauer TW, Hutchins GM. The lung in sickle cell disease. Chest 1982;81:332-337.
72. Bellet PS, Kalinyak KA, Shukla R, Gelfand MJ, Rucknagel DL. Incentive spirometry to prevent acute pulmonary complications in sickle cell disease. N Engl J Med 1995;333:699-703.
73. Trant CA Jr, Casey JR, Hansell D, Cheifetz I, Meliones JN, Ungerleider RM, Browning I, Greeley WJ. Successful use of extracorporeal membrane oxygenation in the treatment of acute chest syndrome in a child with severe sickle cell anemia. ASAIO J 1996;42:236-239.
74. Rees DC, Cervi P, Grimwade D, O'Driscoll A, Hamilton M, Parker NE, Porter JB. The metabolites of nitric oxide in sickle-cell disease. Br J Haematol 1995;91:834-837.
75. Bernini JC, Tkaczewski I, Rogers ZR, Sandler E, Reisch E, Buchanan GR. Dexamethasone therapy for children with acute chest syndrome (ACS) complicating sickle cell disease (SCD): a randomized, double-blind, placebo-controlled pilot study. Blood 1995:86:142 [abstract].
76. Powars D, Weidman JA, Odom-maryon T, Niland JC, Johnson C. Sickle cell chronic lung disease: prior morbidity and the risk of pulmonary failure. Medicine (Baltimore) 1988;67:66-76.
77. Marwick C. Trial halted as sickle cell treatment proves itself. JAMA 1995;273:611.
78. Scott JP, Hillery CA, Brown ER, Misiewicz V, Labotka RJ. Hydroxyurea therapy in children severely affected with sickle cell disease. J Pediatr 1996;128:820-828.
79. Styles LA, Lubin B, Vichinsky E, Lawrence S, Hua M, Test S, Kuypers F. Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea. Blood 1997;89:2554-2559.
80. Claster S, Vichinsky E. First report of reversal of organ dysfunction in sickle cell anemia by the use of hydroxyurea: splenic regeneration. Blood 1996;88:1951-1953.
81. Rodgers GP, Rachmilewitz EA. Novel treatment options in the severe beta-globin disorders. Br J Haematol 1995;91:263-268.
82. El-Hazmi MA, al-Momen A, Kandaswamy S, Huraib S, Harakati M, al-Mohareb F, Warsy AS. On the use of hydroxyurea-erythropoietin combination therapy for sickle cell disease. Acta Haematol (Basel) 1995;94:128-134.
83. El-Hazmi MA, al-Momen A, Warsy AS, Kandaswamy S, Huraib S, Harakati M, al-Mohareb F. The pharmacological manipulation of fetal haemoglobin - trials using hydroxyurea and recombinant human erythropoietin. Acta Haematol (Basel) 1995;93:57-61.
84. Vermylen C, Cornu G. Bone marrow transplantation for sickle cell disease: the European experience. Am J Pediatr Hematol Oncol 1994;16:18-21.
85. Walters MC, Patience M, Leisenring W, Eckman JR, Scott JP, Mentzer WC, Davies SC, Ohene-Frempong K, Bernardin F, Matthews DC, Storb R, Sullivan KM. Bone marrow transplantation for sickle cell disease. N Engl J Med 1996;335:369-376.
86. Brenner M. Gene transfer to hematopoietic cells. N Engl J Med 1996;335:337-339.
87. Moore CM, Ehlayel M, Leiva LE. Sorenson RU. New concepts in the immunology of sickle cell disease. Ann Allergy Asthma Immunol 1996;76:385-400.